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ABSTRACT: Proteoglycan-4 (Prg4) protects synovial joints from arthropathic changes by mechanisms that are incompletely understood.
Parathyroid hormone (PTH), known for its anabolic actions in bone, increases Prg4 expression and has been reported to inhibit articu-
lar cartilage degeneration in arthropathic joints. To investigate the effect of Prg4 and PTH on articular cartilage, 16-week-old Prg4
mutant and wild-type mice were treated with intermittent PTH (1–34) or vehicle control daily for six weeks. Analyses included histolo-
gy of the knee joint, micro-CT of the distal femur, and serum biochemical analysis of type II collagen fragments (CTX-II). Compared to
wild-type littermates, Prg4 mutant mice had an acellular layer of material lining the surfaces of the articular cartilage and menisci,
increased articular cartilage degradation, increased serum CTX-II concentrations, decreased articular chondrocyte apoptosis, increased
synovium SDF-1 expression, and irregularly contoured subchondral bone. PTH-treated Prg4 mutant mice developed a secondary depos-
it overlaying the acellular layer of material lining the joint surfaces, but PTH-treatment did not alter signs of articular cartilage
degeneration in Prg4 mutant mice. The increased joint SDF-1 levels and irregular subchondral bone found in Prg4 mutant mice intro-
duce novel candidate mechanisms by which Prg4 protects articular cartilage.  2012 Orthopaedic Research Society. Published by Wiley
Periodicals, Inc. J Orthop Res 31:183–190, 2013
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The proteoglycan-4 (Prg4) protein products, lubricin
and superficial zone protein, are secreted glycoproteins
expressed in synovial joints by synoviocytes and super-
ficial zone articular chondrocytes.1 Prg4 has well
known boundary lubricating properties in joints, and
has actions inhibiting cell adhesion and suppressing
synoviocyte proliferation.1–3 Characterization of the
joints in Prg4 mutant (Prg4/) mice demonstrated
that Prg4 protects synovial joints from early arthro-
pathic changes, which are non-inflammatory in na-
ture.1 Prg4/ mice have hyperplasia of synovial
intimal cells, disappearance of superficial zone chon-
drocytes, abnormal protein deposition on cartilage sur-
faces, articular cartilage degradation, and precocious
joint failure.1,3
Studies demonstrating an increased coefficient of
friction in loaded joints from Prg4/ mice indicate
that the boundary lubricating properties of Prg4 play
an important role protecting cartilage from load in-
duced wear.4,5 In addition to validating the role of
boundary lubrication, investigations of the Prg4/
mice have introduced novel candidate mechanisms by
which Prg4 protects articular cartilage. Coles et al.3
postulated that lubricin’s ability to form a surface cov-
ering maintains articular cartilage surface integrity by
actions beyond boundary lubrication. Based on find-
ings that Prg4 restricts synovial intimal cell prolifera-
tion via an adhesion dependent mechanism, Rhee
et al.1 speculated that Prg4 actions limiting synovial
cell proliferation protect articular cartilage from physi-
cal invasion by hyperplastic synovium.
PRG4 loss-of-function mutations in humans result
in an autosomal recessive disorder, camptodactyly-
arthropathy-coxa vara-pericarditis (CACP) syndrome,
which is characterized by precocious joint failure reca-
pitulated in the Prg4/ mice.6 In addition to CACP
syndrome, reduced PRG4 levels have been associated
with osteoarthritis (OA) and rheumatoid arthritis
(RA), the two most common degenerative joint condi-
tions.7,8 These findings of decreased PRG4 levels in
arthropathic joints, coupled with studies demonstrat-
ing that exogenous lubricin administration inhibits
the onset and progression of OA in rats suggest that
PRG4 plays a regulatory role in the pathogenesis of
degenerative joint disease.9,10
Intermittent parathyroid hormone (PTH) (1–34) in-
jection, currently the only FDA approved anabolic
therapy for osteoporosis, has been reported to inhibit
the progression of articular cartilage degeneration in
rodent OA models.11,12 Subcutaneous intermittent
PTH injection has recently been shown to increase
Prg4 and proteoglycan expression in articular carti-
lage of degenerating joints responsive to PTH treat-
ment.12 While it has been postulated that PTH
protects articular cartilage from arthropathic changes
by restricting chondrocyte maturation, PTH actions in-
creasing Prg4 and proteoglycan expression in articular
chondrocytes are strong candidate mechanisms medi-
ating PTH chondroprotective properties.11,12
Prg4/ mice were studied to further elucidate
Prg4 functions protecting articular cartilage in vivo. In
light of recent in vivo findings that Prg4 is a PTH-
responsive gene in degenerating articular cartilage
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protected by intermittent PTH-treatment,12 we inves-
tigated the impact of PTH on articular cartilage degen-
eration in the arthropathic joints of adult Prg4/
mice.
METHODS
Breeding of Prg4 Mutant Mice, and Administration of PTH
Prg4 mutant (Prg4/) mice, generated by homologous re-
combination in 129Sv/Ev-derived embryonic stem cells,1 were
backcrossed onto a C57BL6 genetic background. Sixteen-
week-old Prg4/ and Prg4 wild-type (Prg4þ/þ) littermate
mice were given daily subcutaneous injections of either re-
combinant human PTH (1–34) (50 mg/kg) (Bachem, Torrence,
CA) or vehicle (0.9% NaCl) control for 6 weeks. The daily
50mg/kg PTH (1–34) dose, a moderate murine anabolic dose,
was carried out for 6 weeks duration to thoroughly assess
PTH actions on skeletal and joint remodeling. Twenty-four
hours following final injection, mice were sacrificed and tis-
sues harvested.
Histology
Hindlimbs were fixed in 10% phosphate-buffered formalin
(PBF) for 48 h at 48C, and then decalcified in 14%
EDTA pH 7.2 for 14 days at room temperature. Knee joints
were embedded in paraffin. Five micrometer serial sagittal
knee sections were cut, laterally to medially across the knee
joint. H&E staining was performed to assess histopathology.
Safranin O-fast green staining was carried out to evaluate
proteoglycan content and articular cartilage degradation.
The Osteoarthritis Research Society International (OARSI)
osteoarthritis cartilage histopathology assessment system
was adopted to score the severity and extent of articular car-
tilage degradation in the tibial plateau.13,14 All histological
scoring was performed in a blinded manner.
Immunohistochemistry (IHC)
IHC was carried out in sagittal knee sections to analyze the
expression of type 1 collagen (col1), type 2 collagen (col2),
and stromal cell-derived factor-1 (SDF-1). Staining was per-
formed with antibodies to col1, col2, SDF-1, or an IgG
matched isotype control (ABCAM, Cambridge, MA), in con-
junction with a HRP Cell & Tissue Staining Kit (R&D
Systems, Minneapolis, MN). Col1 and col2 labeling were
evaluated to elucidate the cartilaginous make-up of the ec-
topic deposits lining the joint surfaces of Prg4/ mice. SDF-
1 labeling was assessed to characterize the localization and
intensity of SDF-1 expression in synovial cells. Representa-
tive images (20) of the synovium were acquired in the ante-
rior aspect of the knee joint with Olympus FV-500 confocal
microscope, and SDF-1 intensity was graded as (1) low, (2)
moderate, (3) high.
Serum Biochemical Analyses
Via cardiac puncture at euthanasia, serum was isolated, and
stored at 808C. Serum Pre-Clinical CartiLaps ELISA
(Immunodiagnostic Systems, Fountain Hills, AZ) was carried
out in duplicate to assess degradation products of C-terminal
telopeptides of type II collagen (CTX-II).
TUNEL Staining
TUNEL staining was carried out in sagittal knee sections to
assess chondrocyte apoptosis in articular cartilage. The re-
gion of interest was the full thickness cartilage of the tibial
plateau, between the anterior and posterior menisci. Exposed
ends of DNA fragments, induced by apoptotic signals, were
bound by Klenow enzyme and subsequently detected follow-
ing the protocol of the FragELTM DNA Fragmentation Detec-
tion Kit (EMD Chemicals, Gibbstown, NJ).
Immunofluorescence (IF)
SDF-1 IF was carried out in sagittal knee sections to quanti-
tatively assess SDF-1 expression in the synovium. SDF-1 IF
was performed using Zenon Alexa Fluor 488 Rabbit Labeling
Kit (Invitrogen, Carlsbad, CO) and SDF-1 alpha rabbit poly-
clonal AB (ABCAM). Sections were mounted with ProLong
Gold antifade reagent with DAPI (Invitrogen). Representa-
tive images (20) of the synovium were acquired in the ante-
rior aspect of the knee joint with Olympus FV-500 confocal
microscope, and analysis was performed using Image Pro
Plus 5.1 Software.
Micro-Computed Tomography (Micro-CT)
Femurs were fixed in 10% PBF for 48 h at 48C, stored in 70%
EtOH, and scanned in H2O at an 18-mm isotropic voxel size
via eXplore Locus SP (GE Healthcare Pre-Clinical Imaging,
London, ON, Canada). Calibrated three-dimensional images
were reconstructed, and distal femur subchondral bone was
assessed via GE Medical Systems MicroView v2.2 software.
Statistical Analyses
Unpaired t-tests and the Mann–Whitney U-test (semi-
quantitative histological scoring) were performed using
GraphPad Instat Software (GraphPad, Inc., San Diego, CA).
Significance was noted at p < 0.05. Data are presented as
mean  standard error of the mean.
RESULTS
Histological Abnormalities in the Cartilage and Meniscus of
Prg4S/S Mice
Vehicle- and PTH-treated Prg4/ mice had an acellu-
lar layer of material lining the surfaces of the articular
cartilage and menisci (Fig. 1). Rhee et al.1 speculated
that the acellular layer of material lining the Prg4/
joint surfaces is composed of adsorbed proteins from
the synovial fluid. Interestingly, the formation of a sec-
ondary deposit overlaying the acellular layer of mate-
rial lining the surfaces of the articular cartilage and
posterior meniscus was detected in 5 of 10 PTH-
treated Prg4/ mice, whereas 0 of 10 vehicle-treated
Prg4/ mice demonstrated these deposits. PTH-treat-
ment had no observed histologic effects on the joints of
Prg4þ/þ mice (Fig. 1).
Nature of the Deposits Overlying the Joint Surfaces of
Prg4S/S Mice
The acellular layer lining the surfaces of articular car-
tilage and menisci in Prg4/ mice, and the overlaying
secondary deposit noted in PTH-treated Prg4/ mice
were weakly labeled by Safranin O staining, suggest-
ing the deposits were not primarily proteoglycan in na-
ture (Fig. 2). Col2 labeled the most outward layer of
the joint surfaces, but failed to stain underlying layers
(Fig. 2). Similar to a narrow intense band of col2 lining
physiologic joint surfaces in Prg4þ/þ mice, a thin in-
tense band of col2 labeled the periphery of the acellu-
lar layer lining the joint surfaces in vehicle-treated
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Prg4/ mice. Col2 labeling of the secondary deposit in
PTH-treated Prg4/ mice was not restricted superfi-
cially to the periphery but instead permeated through
the deposit. Col1 staining was not localized to the ec-
topic deposits in vehicle- or PTH-treated Prg4/ mice,
demonstrating that the deposits do not have a fibrocar-
tilaginous composition (Fig. 2).
Articular Cartilage Degradation in Prg4S/S Mice
Prg4/ mice had articular cartilage surfaces charac-
terized by fibrillations, fissures, and mid-zone excava-
tions (Fig. 3A). Histologic scoring indicated that the
severity and extent of articular cartilage degradation
was greater in Prg4/ mice, and that degradation
was not altered by PTH-treatment (Fig. 3B). Serum C-
terminal telopeptides of type II collagen (CTX-II) were
assayed as a systemic marker for articular cartilage
degradation. Serum CTX-II levels were increased in
Prg4/ versus Prg4þ/þ mice, and were not affected by
PTH-treatment (Fig. 3C).
Decreased Articular Chondrocyte Apoptosis in
Prg4S/S Mice
TUNEL staining of sagittal knee sections was per-
formed to evaluate the effect of Prg4 and the impact of
PTH-treatment on articular chondrocyte apoptosis.
The frequency of TUNELþ chondrocytes was signifi-
cantly lower in Prg4/ mice. There was no effect of
Figure 1. Knee joint histopathology. Sixteen-week-old Prg4 mutant (Prg4/) and wild-type (Prg4þ/þ) mice were administered inter-
mittent PTH (1–34) (50 mg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injection daily for 6 weeks. Knee joints were isolated
from 22-week-old Prg4 mice for histological evaluation. Representative images of H&E stained sagittal knee sections (4), with (inset)
20 image of the articular cartilage and posterior meniscus (black arrows indicate the acellular layer lining joint surfaces; yellow
arrows indicate the secondary deposit associated with PTH-treatment). [Color figure can be seen in the online version of this article,
available at http://wileyonlinelibrary.com/journal/jor]
Figure 2. Nature of the deposits overlaying the joint surfaces of Prg4 mutant mice. Representative images of meniscal surfaces (40)
in sagittal knee sections labeled with Safranin O-fast green stain, type 1 collagen IHC stain, type 2 collagen IHC stain (black arrows
indicate labeling of the acellular layer lining joint surfaces; orange arrows indicate labeling of the secondary deposit associated with
PTH-treatment). [Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/jor]
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PTH on the frequency of TUNELþ chondrocytes in the
articular cartilage of either Prg4/ or Prg4þ/þ mice
(Fig. 4A–C). Total number of chondrocytes per carti-
lage area were similar in Prg4/ versus Prg4þ/þ mice,
and PTH did not alter total number of chondrocytes
per cartilage area (Fig. 4D).
Increased SDF-1 Expression in the Synovium of
Prg4S/S Mice
Expression of SDF-1, a chemokine best known for
physiologic roles regulating the homing and mobiliza-
tion of hematopoietic cells in the bone marrow,15 was
assessed in the knee joint since increased SDF-1 levels
Figure 3. Articular cartilage degradation. A: Representative images of Safranin O-fast green stained articular cartilage (40) in
sagittal knee sections. B: Bar graph represents the OARSI score (Grade  Stage) for the articular cartilage in the tibial plateau
(n ¼ 8–10/gp). p < 0.01 versus þ/þ VEH; p < 0.01 versus þ/þ PTH. C: Bar graph represents serum C-terminal telopeptides of type
II collagen (CTX-II) levels (n ¼ 8–10/gp). p < 0.01 versus þ/þ VEH; p ¼ 0.08 versus þ/þ PTH. [Color figure can be seen in the
online version of this article, available at http://wileyonlinelibrary.com/journal/jor]
Figure 4. Articular chondrocyte apoptosis. Representative images of TUNEL stained articular chondrocytes in sagittal knee
sections: (A) 40, (B) 100 (black arrows point to selected TUNEL þ chondrocytes). C: Bar graph represents the number of
TUNEL þ chondrocytes per total chondrocytes (n  5/gp). p < 0.01 versus þ/þ VEH; p < 0.001 versus þ/þ PTH. D: Bar graph
represents the total number of chondrocytes per cartilage area (n  5/gp). [Color figure can be seen in the online version of this article,
available at http://wileyonlinelibrary.com/journal/jor]
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have been reported to play a multifaceted role in de-
generative joint disease.16–18 Additional rationale for
evaluating SDF-1 expression in the joints of Prg4/
mice was based on findings that Prg4/ mice have
altered SDF-1 expression in bone marrow.19
SDF-1 IF labeling of sagittal knee sections revealed
increased SDF-1 in the synovium of Prg4/ mice
(Fig. 5A,C). While the Prg4þ/þ synovium had low to
moderate SDF-1 expression limited to the surface
synovium approximating lining synovial intimal
cells, the Prg4/ synovium had intense SDF-1 expres-
sion throughout the hyperplastic tissue matrix. SDF-1
IHC labeling demonstrated the increased SDF-1 ex-
pression in the Prg4/ synovium was localized to
synoviocytes within the hyperplastic tissue matrix
(Fig. 5B,D). There was no difference in SDF-1 expres-
sion in the synovium of vehicle- versus PTH-treated
mice (Fig. 5A–D).
Irregular Subchondral Bone in Prg4S/S Mice
Based on reports that Prg4 is expressed in bone20 and
radiographic findings that Prg4/ mice and humans
afflicted by CACP have periarticular osteopenia,1,6
micro-CT analysis was employed to assess subchondral
bone morphology in the distal femur of Prg4/ mice
(Fig. 6). Sagittal section images of the distal femur
confirmed the expected bone forming anabolic effects
of PTH in the metaphyseal trabecular and cortical
bone of Prg4/ and Prg4þ/þ mice (Fig. 6A). While a
side view (Fig. 6B) and posterior view (Fig. 6C) demon-
strated no obvious morphological differences, the ante-
rior view of the distal femur (Fig. 6D) revealed
abnormalities in the surface contour of the subchon-
dral bone in Prg4/ mice. Specifically, the subchon-
dral bone of the patellar groove had irregular contours
characterized by a medial clefting with elevated lateral
ridges (Fig. 6D). Perpendicular to a line drawn
through the height of the lateral ridges, the depth of
the patellar groove was greater in Prg4/ versus
Prg4þ/þ mice (Fig. 6D,E).
DISCUSSION
The present study investigated Prg4 actions regulating
articular cartilage protection, and tested whether in-
termittent PTH administration could inhibit articular
cartilage degeneration in Prg4 mutant mice. Treat-
ment began at 16 weeks, an age at which Prg4 mutant
mice have an intermediate degree of joint failure, as
Figure 5. Synovium SDF-1 expression. A: Representative images of stromal cell-derived factor-1 (SDF-1) immunofluorescence labeled
synovium (60) (SDF-1/Green and DAPI/Blue) (yellow arrows indicate SDF-1þ synovium) in sagittal knee sections. B: Representative
images of SDF-1 immunohistochemistry labeled synovium (60) (SDF-1/Brown) (black arrows indicate SDF-1þ synovial cells) in sagit-
tal knee sections. C: Bar graph represents SDF-1 area/DAPI area in the synovium (n  4/gp). p < 0.001 versus þ/þ VEH; p < 0.01
versus þ/þ PTH. D: Bar graph represents synovial cell SDF-1 intensity score (n ¼ 4/gp). p < 0.05 versus þ/þ VEH; p < 0.05 versus
þ/þ PTH. [Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/jor]
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indicated by a significant loss of cartilage structure,
stiffness, and frictional properties.1,3 The intermediate
stage was evaluated since this is the period when the
majority of arthropathic patients become symptomatic
and present for clinical care. While intra-articular
injection delivers a controlled local dose to a targeted
joint, PTH was administered via subcutaneous injec-
tion to avoid the risk of iatrogenic trauma to the
joints.
In bone PTH exerts its anabolic actions by
signaling at stromal/osteoblastic cells, the predomi-
nant PTH/PTH-related protein (PTHrP) receptor
(PPR) expressing cells.21 During skeletal development
the PPR is expressed in growth plate prehypertrophic
zone chondrocytes, contributing to a signaling feed-
back loop involving Indian hedgehog which re-
gulates endochondral bone formation.22 Basal PTHrP
appears to regulate articular chondrocyte mainte-
nance23 and PPR expression is upregulated in
articular chondrocytes within OA joints,12 yet the
role of PPR signaling in articular cartilage is
largely unknown. In vitro studies demonstrating
that PTH administration inhibits terminal differentia-
tion of articular chondrocytes, and in vivo OA studies
reporting that PTH treatment significantly suppresses
chondrocyte maturation and apoptosis imply that
PTH protects articular cartilage from arthropathic
changes by restricting chondrocyte maturation.11,12
The recent report that PTH upregulates Prg4 and
proteoglycan expression in articular cartilage within
degenerating joints responsive to PTH, highlights
Prg4 as a strong candidate regulator of PTH actions
inhibiting articular cartilage degeneration in arthro-
pathic joints.12
Surprisingly, the only observed PTH effect in the
joints of Prg4 mutant mice was that PTH induced the
formation of a secondary deposit overlaying the acellu-
lar layer of material lining the surfaces of the articular
cartilage and menisci in half of the PTH-treated mu-
tant animals. The col2 IHC labeling through the full
thickness of the secondary deposit in PTH-treated
Prg4 mutant mice vs. the restricted col2 labeling at
the outward periphery of the acellular layer lining the
joint surfaces in vehicle-treated Prg4 mutant mice sub-
stantiates that the secondary deposit was due to PTH-
treatment. Taking into consideration that subcutane-
ous PTH administration increased Prg4 mRNA and
proteoglycan expression in the articular cartilage of
degenerating OA joints within wild-type mice,12 the
finding that the secondary deposit lining the joint sur-
faces of PTH-treated Prg4 mutant mice was weakly
proteoglycan in nature suggests that Prg4 supports
Figure 6. Subchondral bone morphology. Representative micro-CT images of the distal femur subchondral bone: (A) sagittal
section view, (B) side view, (C) posterior view, (D) anterior view (white line indicates depth of patellar groove). E: Bar graph represents
patellar groove depth (n ¼ 7–8/gp). p < 0.001 versus þ/þ VEH; p < 0.01 versus þ/þ PTH.
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PTH actions increasing proteoglycan expression in
arthropathic joints. Although the composition of this
secondary deposit is unclear at present, its formation
indicates that PTH signaling was functional within
the joints of the Prg4 mutant mice. Similar to reports
that intermittent PTH did not affect articular chondro-
cytes in the knee joints of healthy rats or sham operat-
ed mice,11,12 intermittent PTH had no impact on the
joints of Prg4 wild-type mice.
While the minimal impact of PTH in the arthro-
pathic joints of Prg4 mutant mice implies that Prg4 is
required for PTH to exert chondroprotective effects, it
is unclear whether Prg4 supports PTH actions inhibit-
ing articular cartilage degeneration. Keeping in mind
the lack of Prg4 throughout development in Prg4 mu-
tant mice is different than acutely reduced Prg4 levels
in degenerating joints, it is possible that the damage
caused by the complete absence of Prg4 cannot be
modified by the actions of PTH.
The unexpected finding that TUNNEL staining was
significantly decreased in articular chondrocytes in
Prg4 mutant mice suggests that Prg4 mutant articular
chondrocytes may have cell autonomous alterations
protecting against apoptosis. Taking into consideration
a proposed hypothesis that PTH protects articular car-
tilage from arthropathic changes by restricting chon-
drocyte maturation,11,12 PTH may not have altered
articular cartilage degeneration in Prg4 mutant mice
due to the anti-apoptotic nature of the Prg4 mutant
chondrocytes.
SDF-1 is expressed and secreted by synoviocytes,
and the SDF-1 receptor, CXCR4, is expressed by artic-
ular chondrocytes.24 While there is no known physio-
logic role for SDF-1/CXCR4 paracrine signaling in
synovial joints, increased SDF-1 levels in the joints of
OA and RA patients has been implicated in the degen-
eration of articular cartilage.16–18 In light of in vitro
articular chondrocyte studies demonstrating that su-
pra-physiologic SDF-1 levels stimulate the secretion of
matrix metalloproteinase-3 (MMP-3), MMP-9, and
MMP-13,16,17 we speculate that increased SDF-1 levels
in the joints of Prg4 mutant mice stimulate articular
chondrocytes to release MMPs which mediate the ac-
celerated degradation of articular cartilage. Since
MMP mediated degradation of articular cartilage is re-
quired for the release of type 2 collagen fragments into
the circulation, the increased serum CTX-II levels ob-
served in this study provides evidence that MMP ac-
tivity is upregulated in the joints of Prg4 mutant
mice.
The irregularly contoured subchondral bone surface
of the patellar groove in Prg4 mutant mice illustrates
that Prg4 loss-of-function mutation-induced changes
in the joints are not limited to the synovium and carti-
lage. Of interest, prior work has suggested that
changes in the shape and contour of the subchondral
bone adversely impact the mechanical loading proper-
ties of the adjacent articular cartilage, which has been
speculated to induce pathologic changes in cartilage
structure and integrity.25 Regardless of whether the
irregularly contoured subchondral bone in Prg4 mu-
tant mice is due to Prg4 actions supporting skeletogen-
esis or protecting articular cartilage, the altered
subchondral bone morphology likely contributes to the
degradation of articular cartilage in Prg4 mutant
mice.
This investigation, which did not demonstrate a
protective effect of PTH in the arthropathic joints of
mature Prg4 mutant mice, uncovered novel candidate
mechanisms by which Prg4 protects articular carti-
lage. Increased SDF-1 levels in the joints of Prg4
mutant mice suggest that Prg4 functions as an up-
stream regulator of catabolic cytokine expression in
degenerating joints. Although it is unknown whether
changes in subchondral bone precede or are secondary
to alterations in articular cartilage, the irregularly
contoured subchondral bone likely contributes to the
disruption of the articular cartilage in Prg4 mutant
mice. In summary, Prg4 is a dynamic factor that
protects articular cartilage by diverse mechanisms.
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